JPH08500826A - Lfa−1仲介疾患を処置する方法 - Google Patents
Lfa−1仲介疾患を処置する方法Info
- Publication number
- JPH08500826A JPH08500826A JP6506552A JP50655294A JPH08500826A JP H08500826 A JPH08500826 A JP H08500826A JP 6506552 A JP6506552 A JP 6506552A JP 50655294 A JP50655294 A JP 50655294A JP H08500826 A JPH08500826 A JP H08500826A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- lfa
- dose
- antagonist
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.哺乳動物にLFA−1アンタゴニストの治療的有効量である初期用量を投 与し、続いて1日を基準に計算して該アンタゴニストの初期用量の100%未満 であるLFA−1アンタゴニストの治療的有効量であるその後の間欠的用量を投 与することからなる、哺乳動物においてLFA−1仲介疾患を処置する方法。 2.その後の用量が該アンタゴニストの初期用量の約50%未満である、請求 項1に記載の方法。 3.その後の用量が該アンタゴニストの初期用量の約25%未満である、請求 項1に記載の方法。 4.その後の用量が該アンタゴニストの初期用量の約10%未満である、請求 項1に記載の方法。 5.その後の用量が該アンタゴニストの初期用量の約2%未満である、請求項 1に記載の方法。 6.該疾患が、移植された移植片のまたは移植された移植片による拒絶である 、請求項1に記載の方法。 7.初期投与が移植の実施の前、最中、および後に行なわれる、請求項6に記 載の方法。 8.該哺乳動物に有効量の免疫抑制剤を投与することをさらに含む、請求項1 に記載の方法。 9.該哺乳動物に有効量のシクロスポリンAを投与することをさらに含む、請 求項6に記載の方法。 10.該哺乳動物が人間である、請求項1に記載の方法。 11.該疾患が移植された移植片の拒絶であり、そして移植片のドナーおよび 受容者でHLAクラス11抗原が適合している、請求項10に記載の方法。 12.その後の投与が初期投与より長い時間実施される、請求項1に記載の方 法。 13.初期投与が毎日の投与から成り、その後の投与が大体週に1回以下で投 与される用量である、請求項6に記載の方法。 14.初期投与が移植片の移植後少なくとも1週間毎日のアンタゴニストの投 与からなり、その後の投与が、初期投与の終了後少なくとも約5週間隔週1回以 下のアンタゴニストの投与からなる、請求項13に記載の方法。 15.該アンタゴニストが抗CD11aまたは抗CD18抗体であり、初期投 与が移植実施後約1日ないし4週間で終了し、移植実施前約1週間から移植とほ ぼ同時までに開始される、請求項6に記載の方法。 16.投与が静脈内または皮下注射によりなされる、請求項6に記載の方法。 17.該アンタゴニストが抗LFA−1抗体または抗ICAM−1抗体である 、請求項1に記載の方法。 18.該抗体が抗CD11aまたは抗CD18抗体である、請求項17に記載 の方法。 19.該抗体が抗CD11a抗体である、請求項17に記載の方法。 20.宿主に抗LFA−1抗体の治療的有効量である初期用量を投与し、続い て1日を基準に計算して抗LFA−1抗体の初期用量の100%未満である抗L FA−1抗体の治療的有効量であるその後の用量を投与することからなる、哺乳 動物宿主による移植された移植片のまたは移植された移植片による該宿主の寛容 を増強するための方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93326992A | 1992-08-21 | 1992-08-21 | |
US07/933,269 | 1992-08-21 | ||
PCT/US1993/007845 WO1994004188A1 (en) | 1992-08-21 | 1993-08-20 | Method for treating an lfa-1-mediated disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08500826A true JPH08500826A (ja) | 1996-01-30 |
Family
ID=25463656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6506552A Expired - Lifetime JPH08500826A (ja) | 1992-08-21 | 1993-08-20 | Lfa−1仲介疾患を処置する方法 |
Country Status (14)
Country | Link |
---|---|
US (4) | US5622700A (ja) |
EP (1) | EP0656789B1 (ja) |
JP (1) | JPH08500826A (ja) |
AT (1) | ATE161192T1 (ja) |
AU (1) | AU687755B2 (ja) |
CA (1) | CA2140933A1 (ja) |
DE (1) | DE69315847T2 (ja) |
DK (1) | DK0656789T3 (ja) |
ES (1) | ES2112431T3 (ja) |
GR (1) | GR3026344T3 (ja) |
IL (1) | IL106756A (ja) |
MX (1) | MX9305070A (ja) |
WO (1) | WO1994004188A1 (ja) |
ZA (1) | ZA936128B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002540078A (ja) * | 1999-03-19 | 2002-11-26 | ジェネンテック・インコーポレーテッド | Lfa−1アンタゴニスト投与量の増加によるlfa−1関連疾患の治療 |
JP2003517022A (ja) * | 1999-12-14 | 2003-05-20 | ジェネンテック・インコーポレーテッド | TNF−α又はLFA−1媒介疾患を治療するためのTNF−αアンタゴニスト及びLFA−1アンタゴニスト |
JP2016514090A (ja) * | 2013-02-08 | 2016-05-19 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | Cd3特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着 |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994004188A1 (en) * | 1992-08-21 | 1994-03-03 | Genentech, Inc. | Method for treating an lfa-1-mediated disorder |
FR2700471B1 (fr) * | 1993-01-21 | 1995-04-07 | Pasteur Merieux Serums Vacc | Utilisation d'anticorps monoclonaux anti-LFA-1 pour la préparation d'un médicament destiné à prévenir le rejet des greffes d'organes solides et médicaments obtenus. |
US6884590B1 (en) | 1994-02-11 | 2005-04-26 | Cedars-Sinai Medical Center | Methods of screening for ulcerative colitis and crohn's disease |
US5681699A (en) * | 1994-02-11 | 1997-10-28 | Cedars-Sinai Medical Center | Methods of diagnosing ulcerative colitis and Crohn's disease |
US20020127201A1 (en) * | 1994-07-01 | 2002-09-12 | Dana-Farber Cancer Institute. | Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain |
US6576236B1 (en) * | 1994-07-01 | 2003-06-10 | Dana Farber Cancer Institute | Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain |
AU6256796A (en) * | 1995-06-06 | 1996-12-24 | D. Allen Allen | Method for treating molluscum contagiosum resulting from hiv infection |
US20040197326A1 (en) * | 1995-07-27 | 2004-10-07 | Genentech, Inc. | Method for treatment of allergic asthma |
US5914112A (en) * | 1996-01-23 | 1999-06-22 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
AU5140196A (en) * | 1996-03-29 | 1997-10-22 | Universite Laval | Method of restoring a functional protein in a tissue by cell transplantation |
US6037454A (en) * | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
FR2763072B1 (fr) * | 1997-05-12 | 1999-11-05 | Pasteur Merieux Serums Vacc | Utilisation d'un anticorps monoclonal anti-lfa1 en transplantation renale |
TR199902817T2 (xx) * | 1997-05-17 | 2000-09-21 | Biogen, Inc. | Kar��-uyum sa�lay�c� ba����kl�k reaksiyonlar�n�n, �zellikle a�� reddinin engellenmesi i�in bir CD40:CD154 ba�lanmaya m�dahale maddesinin kullan�m�. |
US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
WO2000029431A1 (en) * | 1998-11-17 | 2000-05-25 | Tanox, Inc. | Bispecific molecules cross-linking itim and itam for therapy |
US6867203B2 (en) | 1998-12-29 | 2005-03-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
US6582698B1 (en) | 1999-03-19 | 2003-06-24 | Genentech, Inc. | Treatment method |
AU2001230920A1 (en) * | 2000-01-14 | 2001-07-24 | Genentech Inc. | Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1 |
AU4574501A (en) | 2000-03-17 | 2001-10-03 | Millennium Pharm Inc | Method of inhibiting stenosis and restenosis |
CA2417432C (en) | 2000-09-01 | 2010-11-02 | The Center For Blood Research, Inc. | Modified polypeptides stabilized in a desired conformation and methods for producing same |
BR0210593A (pt) | 2001-06-22 | 2007-01-02 | Pioneer Hi Bred Int | polinucleotìdeos de defensina e métodos de uso |
DE60325334D1 (de) | 2002-02-05 | 2009-01-29 | Genentech Inc | Proteinaufreinigung |
CA2478925C (en) | 2002-04-26 | 2016-06-07 | Robert Lee Fahrner | Non-affinity purification of proteins |
EP1592776A4 (en) | 2003-02-01 | 2008-06-04 | Tanox Inc | ANTI-HUMAN IGE ANTIBODIES WITH HIGH AFFINITY |
US7834147B2 (en) | 2003-04-28 | 2010-11-16 | Childrens Hospital Medical Center | Saposin C-DOPS: a novel anti-tumor agent |
EP3722309A1 (en) | 2003-07-28 | 2020-10-14 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
AU2004287875B2 (en) | 2003-11-05 | 2011-06-02 | Bausch + Lomb Ireland Limited | Modulators of cellular adhesion |
CA2545653C (en) | 2003-11-21 | 2014-07-08 | Anp Technologies, Inc. | Asymmetrically branched polymer conjugates and microarray assays |
US20050276803A1 (en) * | 2004-04-16 | 2005-12-15 | Genentech, Inc. | Method for augmenting B cell depletion |
WO2005123777A2 (en) * | 2004-06-09 | 2005-12-29 | Genentech, Inc. | Method of treating granuloma annulare or sarcoid |
RU2404991C2 (ru) * | 2004-09-02 | 2010-11-27 | Дженентек, Инк. | АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА FcγRIIB И ИХ ПРИМЕНЕНИЕ |
US7662926B2 (en) * | 2004-09-02 | 2010-02-16 | Genentech, Inc. | Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor |
US7655229B2 (en) * | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
DE102004059357B8 (de) * | 2004-12-03 | 2009-12-03 | Universität Leipzig | Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung |
ATE496297T1 (de) | 2005-05-02 | 2011-02-15 | Anp Technologies Inc | Polymerkonjugat-verbesserte bioassays |
CN101175488B (zh) | 2005-05-17 | 2012-04-18 | 萨可德公司 | 治疗眼病的组合物和方法 |
JP2009530290A (ja) * | 2006-03-16 | 2009-08-27 | ジェネンテック・インコーポレーテッド | Cd4抗体を使用するループスの治療方法 |
US20080279848A1 (en) * | 2006-03-16 | 2008-11-13 | Genentech, Inc. | Methods of treating lupus using CD4 antibodies |
FR2902799B1 (fr) | 2006-06-27 | 2012-10-26 | Millipore Corp | Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide |
EP2046809B1 (en) | 2006-07-19 | 2016-12-07 | The Trustees Of The University Of Pennsylvania | Wsx-1/il-27 as a target for anti-inflammatory responses |
MY183804A (en) | 2006-11-02 | 2021-03-16 | Genentech Inc | Humanized anti-factor d antibodies |
US8569464B2 (en) | 2006-12-21 | 2013-10-29 | Emd Millipore Corporation | Purification of proteins |
WO2008079280A1 (en) | 2006-12-21 | 2008-07-03 | Millipore Corporation | Purification of proteins |
US8362217B2 (en) * | 2006-12-21 | 2013-01-29 | Emd Millipore Corporation | Purification of proteins |
WO2008091740A2 (en) | 2007-01-22 | 2008-07-31 | Genentech, Inc. | Polyelectrolyte precipitation and purification of antibodies |
EP1995309A1 (en) * | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
SG10202005450PA (en) | 2007-07-09 | 2020-07-29 | Genentech Inc | Prevention of disulfide bond reduction during recombinant production of polypeptides |
JP5808037B2 (ja) * | 2007-10-19 | 2015-11-10 | サーコード バイオサイエンス インク. | 糖尿病性網膜症の治療のための組成物及び方法 |
CN103554215B (zh) | 2007-10-30 | 2016-06-15 | 健泰科生物技术公司 | 通过阳离子交换层析进行的抗体纯化 |
WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
CN102065694A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂 |
CN102056485A (zh) * | 2008-04-15 | 2011-05-11 | 萨可德公司 | 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂 |
WO2009128932A1 (en) * | 2008-04-15 | 2009-10-22 | Sarcode Corporation | Delivery of lfa-1 antagonists to the gastrointestinal system |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
US8999702B2 (en) * | 2008-06-11 | 2015-04-07 | Emd Millipore Corporation | Stirred tank bioreactor |
AR077718A1 (es) * | 2008-07-15 | 2011-09-21 | Genentech Inc | Metodos para tratar enfermedades autoinmunes usando anticuerpos anti cd4. formulacion farmaceutica |
EP2321337B2 (en) | 2008-08-14 | 2018-10-10 | Genentech, Inc. | Methods for removing a contaminant using protein displacement ion exchange membrane chromatography |
EP2684570A1 (en) | 2008-09-10 | 2014-01-15 | F. Hoffmann-La Roche AG | Compositions and methods for the prevention of oxidative degradation of proteins |
US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
WO2010074702A1 (en) | 2008-12-16 | 2010-07-01 | Millipore Corporation | Purification of proteins |
CN105037535A (zh) | 2008-12-16 | 2015-11-11 | Emd密理博公司 | 搅拌槽反应器及方法 |
US9580752B2 (en) | 2008-12-24 | 2017-02-28 | Cedars-Sinai Medical Center | Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy |
US8435488B2 (en) | 2009-02-27 | 2013-05-07 | Genentech, Inc. | Methods and compositions for protein labelling |
RU2017138926A (ru) | 2009-08-11 | 2019-02-11 | Дженентек, Инк. | Получение белков в культуральных средах без глутамина |
WO2011028753A1 (en) | 2009-09-01 | 2011-03-10 | Genentech, Inc. | Enhanced protein purification through a modified protein a elution |
US8378105B2 (en) | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
EP2531592A1 (en) | 2010-02-04 | 2012-12-12 | Vivalis | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
JP5937059B2 (ja) | 2010-03-22 | 2016-06-22 | ジェネンテック, インコーポレイテッド | タンパク質含有製剤の安定化に有用な組成物及び方法 |
AP4082A (en) | 2010-03-31 | 2017-03-29 | Boehringer Ingelheim Int | Anti-cd40 antibodies |
JP2013525484A (ja) | 2010-05-03 | 2013-06-20 | ジェネンテック, インコーポレイテッド | タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法 |
ES2754210T3 (es) | 2010-05-17 | 2020-04-16 | Emd Millipore Corp | Polímeros sensibles a estímulos para la purificación de biomoléculas |
MX343604B (es) | 2010-05-28 | 2016-11-11 | Genentech Inc | Disminuir nivel de lactato e incrementar producción de polipéptidos por regulación a la baja de la expresión de lactato dehidrogenasa y piruvato dehidrogenasa quinasa. |
KR102058307B1 (ko) | 2010-06-24 | 2019-12-20 | 제넨테크, 인크. | 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법 |
CN103154032A (zh) | 2010-08-13 | 2013-06-12 | 弗·哈夫曼-拉罗切有限公司 | 用于疾病治疗的针对IL-1β和IL-18的抗体 |
BR112013003223A2 (pt) | 2010-08-23 | 2016-06-07 | Pioneer Hi Bred Int | "polinucleotídeo isolado, cassete de expressão, célula hospedeira, micro-organismo, planta ou parte de planta, método de obtenção de uma planta transformada, composição antipatogênica, método para proteger uma planta contra um patógeno ou uso de um polinucleotídeo isolado" |
WO2012030512A1 (en) | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
JP6126532B2 (ja) | 2010-11-04 | 2017-05-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗il−23抗体 |
CA2824063C (en) | 2011-01-09 | 2020-02-18 | Anp Technologies, Inc. | Hydrophobic molecule-induced branched polymer aggregates and their use |
WO2012095514A1 (en) | 2011-01-14 | 2012-07-19 | Vivalis | Recombinant protein production system |
KR102060389B1 (ko) | 2011-05-21 | 2019-12-31 | 마크로제닉스, 인크. | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 |
KR101949187B1 (ko) | 2011-07-08 | 2019-04-22 | 이엠디 밀리포어 코포레이션 | 일회용 생명공학적 공정용의 개선된 심층 필터 |
MX347164B (es) | 2011-11-16 | 2017-04-18 | Boehringer Ingelheim Int | Anticuerpos anti-il-36r. |
KR20200008022A (ko) | 2011-12-22 | 2020-01-22 | 제넨테크, 인크. | 이온 교환 막 크로마토그래피 |
MX365947B (es) | 2012-03-27 | 2019-06-19 | Genentech Inc | Operaciones de cosecha mejoradas para proteinas recombinadas. |
EP3326649B1 (en) | 2012-05-03 | 2022-02-09 | Boehringer Ingelheim International GmbH | Anti-il-23p19 antibodies |
CA2873646C (en) | 2012-05-18 | 2022-04-26 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
CN110922393A (zh) | 2012-07-25 | 2020-03-27 | 诺华股份有限公司 | Lfa-1抑制剂及其多晶型物 |
EP2919759A4 (en) | 2012-11-14 | 2016-07-20 | Ohio State Innovation Foundation | MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES |
US9393327B2 (en) | 2012-12-19 | 2016-07-19 | Genentech, Inc. | Methods and compositions for radiohalogen protein labeling |
EP2953648B1 (en) | 2013-02-05 | 2021-04-21 | ANP Technologies, Inc. | Nanoparticles containing a taxane and their use |
JP6671276B2 (ja) | 2013-03-27 | 2020-03-25 | セダーズ−シナイ メディカル センター | Tl1a機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復 |
WO2015010108A1 (en) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
SG11201601044XA (en) | 2013-08-12 | 2016-03-30 | Genentech Inc | Compositions and method for treating complement-associated conditions |
BR112016014731A2 (pt) | 2014-01-31 | 2017-09-19 | Boehringer Ingelheim Int | Anticorpos anti-baff |
MA39934A (fr) | 2014-05-01 | 2017-03-08 | Hoffmann La Roche | Variants d'anticorps anti-facteur d et leurs utilisations |
WO2016007752A1 (en) | 2014-07-09 | 2016-01-14 | Genentech, Inc. | Ph adjustment to improve thaw recovery of cell banks |
EP3172339A1 (en) | 2014-07-24 | 2017-05-31 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
CN107922501A (zh) | 2015-09-01 | 2018-04-17 | 勃林格殷格翰国际有限公司 | 抗cd40抗体用于治疗狼疮性肾炎的用途 |
EP3906943A1 (en) | 2015-09-04 | 2021-11-10 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
CN108472382A (zh) | 2015-10-30 | 2018-08-31 | 豪夫迈·罗氏有限公司 | 抗-因子d抗体变体缀合物及其用途 |
EP3368074A2 (en) | 2015-10-30 | 2018-09-05 | Hoffmann-La Roche AG | Anti-factor d antibodies and conjugates |
KR102464372B1 (ko) | 2016-03-17 | 2022-11-04 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
BR112018070139A2 (pt) | 2016-03-29 | 2019-02-05 | Geltor Inc | expressão de proteínas em bactérias gram-negativas em que a razão entre o volume periplasmático e o volume citoplasmático é entre 0,5:1 e 10:1 |
EP3558366A1 (en) | 2016-12-22 | 2019-10-30 | H. Hoffnabb-La Roche Ag | Methods and formulations for reducing reconstitution time of lyophilized polypeptides |
WO2018183173A1 (en) | 2017-03-27 | 2018-10-04 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies combination therapy |
US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
US20210261678A1 (en) | 2018-06-29 | 2021-08-26 | Boehringer Ingelheim International Gmbh | Anti-cd40 antibodies for use in treating autoimmune disease |
CA3104684A1 (en) | 2018-07-03 | 2020-01-09 | Bristol-Myers Squibb Company | Methods of producing recombinant proteins |
MA53859A (fr) | 2018-10-10 | 2022-01-19 | Boehringer Ingelheim Int | Procédé de transfert de gaz de membrane dans une culture de bioréacteur à haute densité |
US11730812B2 (en) | 2019-03-08 | 2023-08-22 | Boehringer Ingelheim International Gmbh | Anti-IL-36R antibody formulations |
MX2021012032A (es) | 2019-04-01 | 2021-11-03 | Genentech Inc | Composiciones y metodos para estabilizar formulaciones que contienen proteinas. |
KR20210151930A (ko) | 2019-04-12 | 2021-12-14 | 젤터, 인코포레이티드 | 재조합 엘라스틴 및 이의 제조 |
WO2021021973A1 (en) | 2019-08-01 | 2021-02-04 | Bristol-Myers Squibb Company | Methods of improving protein productivity in fed-batch cell cultures |
CR20220489A (es) | 2020-03-24 | 2022-10-31 | Genentech Inc | Agentes de fijación a tie2 y métodos de uso. |
TW202229344A (zh) | 2020-09-21 | 2022-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 抗-cd40抗體用於治療發炎病況之用途 |
WO2022066595A1 (en) | 2020-09-22 | 2022-03-31 | Bristol-Myers Squibb Company | Methods for producing therapeutic proteins |
JP2024505674A (ja) | 2021-02-05 | 2024-02-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗il1rap抗体 |
WO2023015234A1 (en) | 2021-08-05 | 2023-02-09 | Bristol-Myers Squibb Company | Cell culture methods for producing therapeutic proteins |
WO2023049687A1 (en) | 2021-09-21 | 2023-03-30 | Bristol-Myers Squibb Company | Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5292636A (en) * | 1986-03-31 | 1994-03-08 | T Cell Diagnostics, Inc. | Therapeutic and diagnostic methods using soluble T cell surface molecules |
US5762933A (en) * | 1987-01-05 | 1998-06-09 | Institut National De La Sante Et De La Recherche Medicale | Method for preventing and treating graft failure in a human patient using a monoclonal antibody specific for leucocyte functional antigen LFA-1 |
JPH01502879A (ja) * | 1987-02-26 | 1989-10-05 | ダナ ファーバー キャンサー インスティテュート | Lfa―1のクローニング |
DE3854536T2 (de) * | 1987-05-04 | 1996-03-07 | Dana Farber Cancer Inst Inc | Interzellulare Adhäsions-Moleküle und deren Bindungsliganden. |
US5284931A (en) * | 1987-05-04 | 1994-02-08 | Dana Farber Cancer Institute | Intercellular adhesion molecules, and their binding ligands |
US5403919A (en) * | 1987-08-11 | 1995-04-04 | Board Of Trustees Of The Leland Stanford Junior University Stanford University | Method to control leukocyte extravasation |
US5538724A (en) * | 1987-08-11 | 1996-07-23 | The Board Of Trustees For The Leland Stanford Junior Univ. | Method of control leukocyte extravasation |
US4797277A (en) * | 1987-09-22 | 1989-01-10 | Pharmacia Ab | Method for reperfusion therapy |
DE3852374T2 (de) * | 1987-11-02 | 1995-05-04 | Baylor College Medicine | Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen. |
US5002869A (en) * | 1987-11-02 | 1991-03-26 | Dana-Farber Cancer Institute | Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes |
US5395929A (en) * | 1987-12-15 | 1995-03-07 | Dana Farber Cancer Institute | Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor |
US5071964A (en) * | 1988-05-04 | 1991-12-10 | Dana-Farber Cancer Institute, Inc. | Protein micelles |
US5147637A (en) * | 1988-06-07 | 1992-09-15 | The Rockefeller University | Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma |
WO1990008187A1 (en) * | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
CA2008368C (en) * | 1989-01-24 | 2003-04-08 | Jeffrey Greve | Soluble molecule related to but distinct from icam-1 |
US5235049A (en) * | 1989-01-24 | 1993-08-10 | Molecular Therapeutics, Inc. | Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1 |
NO900155L (no) * | 1989-01-24 | 1990-07-25 | Molecular Therapeutics Inc | Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1. |
WO1990010652A1 (en) * | 1989-03-09 | 1990-09-20 | Dana Farber Cancer Institute | Method of treating viral infections using lfa-1 |
ES2097747T3 (es) * | 1989-03-09 | 1997-04-16 | Blood Res Center | Molecula de adhesion intercelular 2 y sus ligandos de union. |
GB8912497D0 (en) * | 1989-05-31 | 1989-07-19 | Cobbold Stephen P | Monoclonal antibodies |
US5690933A (en) * | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
CA2033347C (en) * | 1989-06-02 | 2000-02-29 | James E. Hildreth | Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore |
GB9009549D0 (en) * | 1990-04-27 | 1990-06-20 | Celltech Ltd | Recombinant antibody and method |
GB9009548D0 (en) * | 1990-04-27 | 1990-06-20 | Celltech Ltd | Chimeric antibody and method |
WO1991018011A1 (en) * | 1990-05-15 | 1991-11-28 | Swinburne Limited | Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof |
AU8631991A (en) * | 1990-08-27 | 1992-03-17 | Cetus Corporation | Cd18 peptide medicaments for the treatment of disease |
DK0546076T3 (da) * | 1990-08-31 | 1998-10-19 | Boehringer Ingelheim Pharma | Anvendelse af anti-ICAM antistoffer til fremstilling af et lægemiddel til behandling af endotoksiskshock |
LU91067I2 (fr) * | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
WO1993006864A1 (en) * | 1991-10-01 | 1993-04-15 | The General Hospital Corporation | Preventing allograft rejection with antibodies to adhesion molecules |
US5854070A (en) * | 1992-07-16 | 1998-12-29 | Icos Corporation | Murine and humanizer 23F2G antibodies and cell lines expressing said antibodies |
EP0604647A4 (en) * | 1992-07-16 | 1996-09-25 | Icos Corp | Alleviation of symptoms associated with inflammatory disease states. |
WO1994004188A1 (en) * | 1992-08-21 | 1994-03-03 | Genentech, Inc. | Method for treating an lfa-1-mediated disorder |
-
1993
- 1993-08-20 WO PCT/US1993/007845 patent/WO1994004188A1/en active IP Right Grant
- 1993-08-20 AT AT93920241T patent/ATE161192T1/de not_active IP Right Cessation
- 1993-08-20 ES ES93920241T patent/ES2112431T3/es not_active Expired - Lifetime
- 1993-08-20 EP EP93920241A patent/EP0656789B1/en not_active Expired - Lifetime
- 1993-08-20 CA CA002140933A patent/CA2140933A1/en not_active Abandoned
- 1993-08-20 DE DE69315847T patent/DE69315847T2/de not_active Expired - Fee Related
- 1993-08-20 JP JP6506552A patent/JPH08500826A/ja not_active Expired - Lifetime
- 1993-08-20 ZA ZA936128A patent/ZA936128B/xx unknown
- 1993-08-20 AU AU50836/93A patent/AU687755B2/en not_active Ceased
- 1993-08-20 MX MX9305070A patent/MX9305070A/es not_active IP Right Cessation
- 1993-08-20 DK DK93920241T patent/DK0656789T3/da active
- 1993-08-22 IL IL106756A patent/IL106756A/en not_active IP Right Cessation
-
1995
- 1995-05-02 US US08/432,543 patent/US5622700A/en not_active Expired - Lifetime
-
1998
- 1998-03-13 GR GR980400529T patent/GR3026344T3/el unknown
-
2002
- 2002-07-29 US US10/208,112 patent/US20020197248A1/en not_active Abandoned
-
2003
- 2003-12-02 US US10/727,383 patent/US20040120960A1/en not_active Abandoned
-
2005
- 2005-07-26 US US11/190,410 patent/US20050281817A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002540078A (ja) * | 1999-03-19 | 2002-11-26 | ジェネンテック・インコーポレーテッド | Lfa−1アンタゴニスト投与量の増加によるlfa−1関連疾患の治療 |
JP2003517022A (ja) * | 1999-12-14 | 2003-05-20 | ジェネンテック・インコーポレーテッド | TNF−α又はLFA−1媒介疾患を治療するためのTNF−αアンタゴニスト及びLFA−1アンタゴニスト |
JP2016514090A (ja) * | 2013-02-08 | 2016-05-19 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | Cd3特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着 |
JP2019178142A (ja) * | 2013-02-08 | 2019-10-17 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | Cd3特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着 |
Also Published As
Publication number | Publication date |
---|---|
DE69315847D1 (de) | 1998-01-29 |
GR3026344T3 (en) | 1998-06-30 |
WO1994004188A1 (en) | 1994-03-03 |
MX9305070A (es) | 1994-04-29 |
US20050281817A1 (en) | 2005-12-22 |
ATE161192T1 (de) | 1998-01-15 |
ZA936128B (en) | 1995-02-20 |
IL106756A0 (en) | 1993-12-08 |
IL106756A (en) | 2006-07-05 |
EP0656789B1 (en) | 1997-12-17 |
DE69315847T2 (de) | 1998-06-25 |
ES2112431T3 (es) | 1998-04-01 |
US20040120960A1 (en) | 2004-06-24 |
US5622700A (en) | 1997-04-22 |
EP0656789A1 (en) | 1995-06-14 |
US20020197248A1 (en) | 2002-12-26 |
CA2140933A1 (en) | 1994-02-22 |
AU5083693A (en) | 1994-03-15 |
DK0656789T3 (da) | 1998-08-24 |
AU687755B2 (en) | 1998-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08500826A (ja) | Lfa−1仲介疾患を処置する方法 | |
US6844011B1 (en) | Methods for inhibiting rejection of transplanted tissue | |
EP0700402B1 (en) | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies | |
US20070244053A1 (en) | Use of a CD40:CD154 binding interruptor to prevent counter-adaptive immune responses, particularly graft rejection | |
US20060292142A1 (en) | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies | |
JP2002502824A (ja) | 同種移植における補刺激遮断および混合キメラ現象 | |
JP2001501607A (ja) | 免疫調節のためのcd45r白血球抗原に対する抗体の利用 | |
JPH10501815A (ja) | 抗原特異的t細胞応答の阻害方法 | |
JP2763197B2 (ja) | トレランスを誘導するためのモノクローナル抗体 | |
US20120269806A1 (en) | Methods of inducing tolerance | |
Prabhune et al. | Mixed allogeneic chimerism and tolerance to composite tissue allografts | |
Chong et al. | Transplantation tolerance and its outcome during infections and inflammation | |
Qian et al. | Molecular mechanisms of immunity in corneal allotransplantation and xenotransplantation | |
OSORIO et al. | PROLONGATION OF IN VIVO MOUSE ISLET ALLOGRAFT SURVIVAL BY MODULATION OF MHC CLASS I ANTIGENs | |
JP2001506122A (ja) | 免疫抑制作用を有するモノクローナル抗体断片 | |
Pilat et al. | Blockade of adhesion molecule lymphocyte function–associated antigen-1 improves long-term heart allograft survival in mixed chimeras | |
ALFREY et al. | Tolerance induced by direct inoculation of donor antigen into the thymus in low and high responder rodents | |
Dehoux et al. | EFFECTS ON HUMAN AND NONHUMAN PRIMATE IMMUNE RESPONSE OF A NEW RAT ANTI-CD2 MONOCLONAL ANTIBODY1 | |
Bigaud et al. | NVP-AEB071 (AEB), THE NOVEL ORAL INHIBITOR OF PROTEIN KINASE C (PKC) AND EARLY T-CELL ACTIVATION, PROLONGS NON-HUMAN PRIMATES (NHP) KIDNEY ALLOGRAFT SURVIVAL WHEN COMBINED WITH EVEROLIMUS (RAD), ERL080 (ERL) OR FTY720 (FTY) WITHOUT CALCINEURIN INHIBITOR (CNI). | |
Iwata et al. | Immunosuppression by anti-ICAM-1 and anti-LFA-1 monoclonal antibodies of free and vascularized skin allograft rejection | |
Ohajekwe et al. | PREVENTION OF GRAFT-VERSUS-HOST DISEASE AND THE INDUCTION OF TRANSPLANT TOLERANCE BY LOW-DOSE UV-B IRRADIATION OF BM CELLS COMBINED WITH CYCLOSPORINE IMMUNOSUPPRESSION1 | |
JPH06298654A (ja) | 抗原特異的免疫抑制剤 | |
Shachner et al. | Direct assessment of the role of NK cells in autoimmune diabetes | |
Sun et al. | Immunology of transplantation | |
Gorantla | Mechanisms that mediate graft versus host disease after composite tissue allotransplantation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041005 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050105 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050404 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070508 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080128 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090128 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090128 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100128 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110128 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110128 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120128 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120128 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130128 Year of fee payment: 13 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130128 Year of fee payment: 13 |